• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Tavenner Withdraws Fractious Part D Changes

Article

Under pressure from the industry and Congress, the Centers for Medicare & Medicaid Services is withdrawing several proposed changes to the Medicare drug program, but still charging ahead with others that could prove disruptive.

Under pressure from the industry and Congress, the Centers for Medicare & Medicaid Services is withdrawing several proposed changes to the Medicare drug program, but still charging ahead with others that could prove disruptive.

In a large batch of Medicare Part D proposed regulations first published in January, CMS announced plans to end three protected classes of drugs, standardize preferred pharmacy networks, extend negotiated drug pricing across the program and limit the number of plans available in a region, among other things the agency argued would collectively help save $1 billion over five years.

Those proposals and others drew criticism from various corners of Congress and the health, insurance and pharmaceutical industries, especially the elimination of the protected classes of antidepressants, antipsychotics and immunosuppressants and a new interpretation of the Part D “non-interference” clause that would give every pharmacy the ability to contract with plans under preferred terms and conditions.

Read the full story here: http://bit.ly/1iAmp2S

Source: Healthcare Payer News

Related Videos
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
David Awad, PharmD, BCOP
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Ali Khawar
Ali Khawar
Emma Achola-Kothari, PhD
Dr Emma Achola-Kothani
Dr Emma Achola-Kothari
Casey Koch, PharmD, sitting for a video interview
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.